ストックスクリーナーアプリを入手
107.34
0.15%
-0.16
アフターアワーズ：
107.34
前日終値:
$107.50
開ける：
$105.02
24時間の取引高:
840.69K
Relative Volume:
0.94
時価総額：
$25.80B
収益：
$2.97B
当期純損益:
$-812.83M
株価収益率:
-31.61
EPS:
-3.3962
ネットキャッシュフロー:
$-1.24B
1週間 パフォーマンス:
-6.91%
1か月 パフォーマンス:
-0.16%
6か月 パフォーマンス:
-13.27%
1年 パフォーマンス:
+33.04%
1日の値動き範囲:
$104.64
$107.48
1週間の範囲:
$104.64
$114.91
52週間の値動き範囲:
$76.53
$131.49
Biontech Se Adr Stock (BNTX) Company Profile
BNTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
107.34 | 25.84B | 2.97B | -812.83M | -1.24B | -3.3962 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-05-29 | 開始されました | Goldman | Neutral |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-01-10 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2024-11-19 | 開始されました | Berenberg | Buy |
| 2024-11-19 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-11-08 | アップグレード | Goldman | Neutral → Buy |
| 2024-09-24 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-09-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-08-07 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-08-02 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-14 | 開始されました | Evercore ISI | In-line |
| 2024-02-23 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-05 | 開始されました | Oppenheimer | Perform |
| 2023-12-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-10-16 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-17 | アップグレード | Redburn | Neutral → Buy |
| 2022-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-08-17 | 開始されました | Cowen | Market Perform |
| 2022-07-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2021-12-16 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-10-07 | 開始されました | Jefferies | Hold |
| 2021-08-11 | アップグレード | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-16 | ダウングレード | Redburn | Neutral → Sell |
| 2021-05-18 | 開始されました | Goldman | Neutral |
| 2021-05-11 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-08-03 | 再開されました | Berenberg | Buy |
| 2020-07-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-06-30 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 開始されました | H.C. Wainwright | Neutral |
| 2020-01-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | ダウングレード | UBS | Buy → Neutral |
| 2019-11-05 | 開始されました | Wolfe Research | Outperform |
| 2019-11-04 | 開始されました | Berenberg | Buy |
| 2019-11-04 | 開始されました | BofA/Merrill | Buy |
| 2019-11-04 | 開始されました | Canaccord Genuity | Buy |
| 2019-11-04 | 開始されました | JP Morgan | Overweight |
| 2019-11-04 | 開始されました | SVB Leerink | Outperform |
| 2019-11-04 | 開始されました | UBS | Buy |
すべてを表示
Biontech Se Adr (BNTX) 最新ニュース
BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - TipRanks
Moderna's Key Patent Win Overshadowed By Gloomy Outlook - Benzinga
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know - Yahoo Finance
Cancer Vaccine Market Research Service Featuring the Top 5 Developers and Pipeline Activities - GlobeNewswire Inc.
Best Momentum Stocks to Buy for July 29th - Yahoo Finance
New Strong Buy Stocks for July 29th - Yahoo Finance
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares Acquired by Kestra Private Wealth Services LLC - Defense World
Cerity Partners LLC Invests $357,000 in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union - Ariva
BioNTech’s Promising Study on Pancreatic Cancer Treatment: Market Implications - TipRanks
Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Genmab and BioNTech Launch Promising Study for Advanced Colorectal Cancer Treatment - TipRanks
BioNTech’s New Study on PDAC Treatment: Key Insights for Investors - TipRanks
BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN
Pfizer and BioNTech’s New Shingles Vaccine Study: What Investors Need to Know - TipRanks
BioNTech’s BNT327 Trial: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks
BioNTech’s Promising Lung Cancer Trial: A Potential Game-Changer for NSCLC Treatment - TipRanks
BioNTech Announces Ryan Richardson to Step Down from the Management Board17.07.25News - Ariva
BioNTech’s DYNASTY-Breast02 Study: A New Hope for Metastatic Breast Cancer? - TipRanks
OneDigital Investment Advisors LLC Makes New Investment in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer - TipRanks
BioNTech’s Latest Clinical Trial: A New Hope for Lung Cancer Treatment? - TipRanks
BioNTech’s Phase II Trial: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks
Regeneron and BioNTech’s Promising Lung Cancer Trial: What Investors Need to Know - TipRanks
BioNTech SE Receives Buy Rating from BMO Capital with $143 Price Target - AInvest
Genmab and BioNTech’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
GAMMA Investing LLC Sells 334 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks
Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope in Cancer Treatment - TipRanks
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech’s Cancer Therapy Study Withdrawn: Implications for Investors - TipRanks
BioNTech’s BNT151 Study Update: Early Termination and Market Implications - TipRanks
BioNTech ADR Earns Relative Strength Rating Upgrade - MSN
BioNTech’s Latest Clinical Trial: A New Hope for NSCLC Treatment? - TipRanks
What is HC Wainwright’s Forecast for BioNTech Q3 Earnings? - Defense World
BioNTech ADR Gets Relative Strength Rating Upgrade - Investor's Business Daily
BioNTech’s Promising Phase II Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech SE’s Promising Study on Pancreatic Cancer Treatment: What Investors Need to Know - TipRanks
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Zacks Investment Research
Equities Analysts Issue Forecasts for BioNTech Q4 Earnings - Defense World
BioNTech (BNTX) – Analysts’ Recent Ratings Changes - Defense World
HC Wainwright Estimates BioNTech’s Q4 Earnings (NASDAQ:BNTX) - Defense World
Market Update: Abercrombie & Fitch Co (ANF) Sees Positive Movement, Closing at 75.00 - DWinneX
Biontech Se Adr (BNTX) 財務データ
収益
当期純利益
現金流量
EPS
2.65%
0.70%
大文字化:
|
ボリューム (24 時間):